|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Amyotrophic Lateral Sclerosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Motor Neuron Disease | |||||
| Sclerosis | |||||
| 3 | More general conditions related to this trial | ||||
| Central Nervous System Diseases | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Neuromuscular Diseases | |||||
| Pathologic Processes | |||||
| Spinal Cord Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| sodium phenylbutyrate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| 4-phenylbutyric acid | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Department of Veterans Affairs | |||||
| Muscular Dystrophy Association | |||||